211 related articles for article (PubMed ID: 19470738)
41. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
42. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
43. [Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].
Kita A; Nakahara T; Takeuchi M; Kinoyama I; Yamanaka K; Minematsu T; Mitsuoka K; Fushiki H; Miyoshi S; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):198-203. PubMed ID: 20948154
[No Abstract] [Full Text] [Related]
44. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
45. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Chen J; Pise-Masison CA; Shih JH; Morris JC; Janik JE; Conlon KC; Keating A; Waldmann TA
Blood; 2013 Mar; 121(11):2029-37. PubMed ID: 23321252
[TBL] [Abstract][Full Text] [Related]
46. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.
Glaros TG; Stockwin LH; Mullendore ME; Smith B; Morrison BL; Newton DL
Cancer Chemother Pharmacol; 2012 Jul; 70(1):207-12. PubMed ID: 22526412
[TBL] [Abstract][Full Text] [Related]
47. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
48. The small molecule survivin inhibitor YM155 may be an effective treatment modality for colon cancer through increasing apoptosis.
Li WL; Lee MR; Cho MY
Biochem Biophys Res Commun; 2016 Mar; 471(2):309-14. PubMed ID: 26855135
[TBL] [Abstract][Full Text] [Related]
49. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
50. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
Jameson MB; Rischin D; Pegram M; Gutheil J; Patterson AV; Denny WA; Wilson WR
Cancer Chemother Pharmacol; 2010 Mar; 65(4):791-801. PubMed ID: 20012293
[TBL] [Abstract][Full Text] [Related]
51. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Kurzrock R; Gabrail N; Chandhasin C; Moulder S; Smith C; Brenner A; Sankhala K; Mita A; Elian K; Bouchard D; Sarantopoulos J
Mol Cancer Ther; 2012 Feb; 11(2):308-16. PubMed ID: 22203732
[TBL] [Abstract][Full Text] [Related]
52. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
[TBL] [Abstract][Full Text] [Related]
54. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
55. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
56. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
57. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Clemens MR; Gladkov OA; Gartner E; Vladimirov V; Crown J; Steinberg J; Jie F; Keating A
Breast Cancer Res Treat; 2015 Jan; 149(1):171-9. PubMed ID: 25547219
[TBL] [Abstract][Full Text] [Related]
58. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
59. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
[TBL] [Abstract][Full Text] [Related]
60. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]